1-3 of 3
Kimberly Stegmaier
Close
Sort by
Journal Articles

DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia

Amy N. Sexauer, Gabriela Alexe, Karin Gustafsson, Elizabeth Zanetakos, Jelena Milosevic, Mary Ayres, Varsha Gandhi, Yana Pikman, Kimberly Stegmaier, David B. Sykes
Journal: Blood Advances
Blood Adv (2023) 7 (21): 6685–6701.
https://doi.org/10.1182/bloodadvances.2023010337
Published: 2023
Includes: Supplemental data
Journal Articles

Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma

Clinical Trials & Observations
Yana Pikman, Amy Saur Conway, Amanda L. Robichaud, Samuel Kitara, Alanna J. Church, Alyssa L. Kennedy, Lewis B. Silverman, Amy L. Billett, David M. Weinstock, Marian H. Harris, Kimberly Stegmaier
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1265–1269.
https://doi.org/10.1182/bloodadvances.2019001256
Published: 2020
Journal Articles

The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy

Suhu Liu, Anna E. Marneth, Gabriela Alexe, Sarah R. Walker, Helen I. Gandler, Darwin Q. Ye, Katherine Labella, Radhika Mathur, Patricia A. Toniolo, Michelle Tillgren, Prafulla C. Gokhale, David Barbie, Ann Mullally, Kimberly Stegmaier, David A. Frank
Journal: Blood Advances
Blood Adv (2018) 2 (23): 3428–3442.
https://doi.org/10.1182/bloodadvances.2018016733
Published: 2018
Includes: Supplemental data